UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/173,831	10/16/98	RUDLAND	P 32040PCTUSA-

HM22/1215

BAKER & BOTTS
30 ROCKEFELLER PLAZA
NEW YORK NY 10112-0228

EXAMINER	
KAUSHAL,S	
ART UNIT	**PAPER NUMBER**
1633	13

DATE MAILED: 12/15/00

Pl as find below and/or attached an Office communication concerning this application or proce ding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)	
	09/173,821	RUDLAND ET AL.	
	Examiner	Art Unit	
	Sumesh Kaushal	1633	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *04 November 2000* .

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1,3,4,6-9,13,and 15-29* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1,3,4,6-9,13, and 15-29* is/are rejected.

7)☒ Claim(s) *19and 20* is/are objected to.

8)☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are objected to by the Examiner.

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).

Attachment(s)

15) ☐ Notice of References Cited (PTO-892)
16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
18) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
19) ☐ Notice of Informal Patent Application (PTO-152)
20) ☐ Other:

DETAILED ACTION

Continued Prosecution Application

The request filed on 11/14/00 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/173,821 is acceptable and a CPA has been established. An action on the CPA follows.

The applicant's response filed on Paper No.9, filed 02/23/00 has been fully considered but they are not persuasive for the reasons set forth in the earlier office action (Paper No.7, 08/17/99). Claims 2, 5, 10-12 and 14 are canceled. Claims 1, 3-4, 6-8, 13 and 15-24 are amended. Newly filed claims 25-29 are entered. Claims 1, 3-4, 6-9 and 15-29 are pending in this application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Objections

Claims 19 and 20 are objected to under 37 CFR 1.75© as being in improper form because a multiple dependent claim should refer to other claims in the alternative only and/or cannot depend from any other multiple dependent claim. See MPEP § 608.01(n).

Claim Rejections - 35 USC § 112

Claims 1, 3-4, 13, 15-17, 19-29 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for i) a cell line derived from a transgenic rat comprising: B2LT1 rat mammary cells (MMTV-SV40tsA58) and NF2 rat brain cells (NS-LtsA58) ii) transgenic rats comprising: MMTVLTR-TGFα and MMTVLTR-C-erb-B-2, does not reasonably provide enablement for any and all transgenic cell lines and/or transgenic rats comprising any and all conditional transforming genes or immortalizing genes or cell cycle affecting genes and cell type specific promoters. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention **commensurate in scope** with these claims.

1. Applicant's arguments filed 02/23/00, page 8, para.3, have been fully considered. Applicant's argument that recitation of mammal to rat and deletion of reference to mammary, liver and kidney cell line obviate this rejection is not persuasive because the instant claims after the amendment read upon a transgenic rat comprising any and all conditional transforming genes or immortalizing genes or cell cycle affecting genes and cell type specific promoters. However, the instant specification is only enabled for i) cell line derived from transgenic rat comprising: B2LT1 rat mammary cells (MMTV-SV40tsA58) and NF2 rat brain cells (NS-LtsA58) ii) transgenic rats comprising: MMTVLTR-TGFα and MMTVLTR-C-erb-B-2. It is important to note that, the scope of the claims include rats encoding any and all conditional transforming genes or immortalizing genes or cell cycle affecting genes and cell type specific promoters. As stated in earlier official action (page 6, para.1), the transgene expression and physiological consequences of transgene products are not always accurately predictable because cis elements are controlled differently by various transacting factors in the genome of an animal. Therefore, the skilled artisan at the time of filing would be lacking a reasonable expectation of success for making neuronal transgenic cell lines derived from transgenic rat(s), comprising any and all conditional transforming genes or immortalizing genes or cell cycle affecting genes and

cell type specific promoters, without having to engage in an undue amount of experimentation for the breadth of the claims.

Claim Rejections - 35 USC § 103

Claims 1, 3-4, 6-9, 13, 15-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Noble at al (WO 91/13150, 1991), Stocklin et al (J. Cell Bio. 122(1):199-208, 1993), and Moses JH (Br. J. Cancer. 69(21):1, 1994) in view of Reeben et al (Biochem. Biophy. Res. Com. 192(2):465-470, 1993) and Yazdanbakhsh et al (Nuc. Acid. Res. 21(3):455-61, 1993) in view of Leder et al (US Pat No. 5087571, 1992) and further in view of Hammer et al (US Pat.. No. 5489742, 1996). The references cited herein are of record in the official action(s) mailed on 8/17/99 and 5/15/00.

Noble et al teaches transgenic animals and cell lines from any cell type of the animal body, wherein the cell line comprises **SV40tsA58** immortalizing gene (fig-1; page 34, line 1-20, page 35-40, page 50, line 19, page 53, line 22, page 56, line 16, page 59, example-3, page 61 example-4 page 64, example-5 page 69, example-6, page 74, example-7).

Stocklin et al teaches a transgenic mice wherein the human **c-erbB-2** is operably linked to MMTV enhancer/promoter sequence wherein the transgene is expressed in kidney, lung, mammary, muscle, spleen, brain and liver cells (page 200, col.2 para.5, page 201, fig-1, col.2 para 2-3, page 202, table-II).

Moses teaches a tarnsgenic mice expressing a gene encoding **hu TGF-a** under the control of MMTV enhancer/promoter (page 1, s1).

However, Noble et al, Stocklin et al and Mosses does not teach the use of **human neurofilament (NF-L) promoter** to derive the expression of **SV40tsA58, c-erbB-2 and TGF-a** genes.

Yazdanbakhsh et al teaches **human neurofilament (NF-L) promoter** which regulates neuronal-specific expression (page 455, abstract).

Leder et al teaches method of providing a cell line from a transgenic mice encoding a transforming oncogne operably linked to mammary specific promoter MMTVLTR (col.4 line 13-22, col.9 line 11-20). Leder et al also teaches the use of transgenic mice for testing a material suspected of being a carcinogen (col.8 line 50-68). The cited art also teaches a method of testing a material for its ability to confer protection against the development of neoplasms using transgenic animals (col.9 line 1-9).

Although the combination of Noble et al, Stocklin et al, Mosses, Yazdanbakhsh et al Leder et al teaches a transgenic mice and/or cell line and a method of screening carcinogens, wherein in the transgenic cell the human neurofilament (NF-L) promoter to derive the expression of SV40tsA58, c-erbB-2 and TGF-a genes, it does not teach the making of a transgenic rat encoding the same.

Hammer et al teaches a method for producing transgenic rats, by super ovulating a female rat by continuous supply of FSH hormone using a mini-pump and introduction of the selected transgene into the fertilized eggs (col.15 line 60-67, col.1, line 1-17).

Thus, it would have been obvious to one ordinary skill in the art at the time of filing to have substituted the transgenic mice (encoding human neurofilament promoter which derives the expression of SV40tsA58, c-erbB-2 or TGF-a gene) as taught by Noble et al, Stocklin et al, Mosses and Yazdanbakhsh et al with a transgenic rat as taught by Hammer et al. It would have been further obvious to test a material suspected of being carcinogen a transgenic rat as taught by Leder. One would have been motivated to do this because rats are widely used in biomedical

application or proceeding is assigned as (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703) 308-0196.

S. Kaushal, AU 1633

DEBORAH J. R. CLARK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

US 091738210GP1

Creation date: 02-02-2004
Indexing Officer: NIFILL - NICOLE IFILL
Team: OIPEBackFileIndexing
Dossier: 09173821

Legal Date: 01-16-2001

No.	Doccode	Number of pages
1	CTMS	3

Total number of pages: 3

Remarks:

Order of re-scan issued on .....